{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:00:24Z","timestamp":1760043624826,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This survey aims to understand the current UK practice for non-small cell lung carcinoma (NSCLC) and identify barriers that may impact patient treatment and outcomes. In March\u2013June 2021, 57 interviews were conducted with healthcare professionals involved in the secondary care management of patients with NSCLC. Most respondents performed genetic testing at onsite and non-genomic laboratory hub (GLH) offsite locations. The most common genetic tests were EGFR T790M variant (100%), EGFR exon 18-21 covered (95%) and BRAF (93%). No targeted therapy (TT) available (69%), lack of access to a TT (54%) or excessive molecular testing turnaround times (39%) were the most common reasons for using an immuno-oncology therapy over a TT in the first-line setting. The survey highlights variation in mutation testing practices across the UK, which may impact treatment decisions and contribute to health outcome inequality.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad134","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:37:13Z","timestamp":1686663433000},"page":"e699-e702","source":"Crossref","is-referenced-by-count":3,"title":["Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-6886","authenticated-orcid":false,"given":"Shobhit","family":"Baijal","sequence":"first","affiliation":[{"name":"University Hospital Birmingham NHS Trust , Birmingham , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-4813","authenticated-orcid":false,"given":"Philip","family":"Crosbie","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust , Manchester , UK"},{"name":"Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-6927","authenticated-orcid":false,"given":"Jackie","family":"Fenemore","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketul","family":"Desai","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"10","key":"2023080322072255900_CIT0001","doi-asserted-by":"crossref","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2023080322072255900_CIT0002","first-page":"1","article-title":"Immunotherapy in non-small cell lung cancer: update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J Clin Transl Res"},{"year":"2022","key":"2023080322072255900_CIT0003"},{"year":"2020","author":"Royal College of Physicians","key":"2023080322072255900_CIT0004"},{"issue":"6","key":"2023080322072255900_CIT0005","first-page":"100176","article-title":"Biomarker testing for people with advanced lung cancer in England","volume":"2","author":"Adizie","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"2023080322072255900_CIT0006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"issue":"3","key":"2023080322072255900_CIT0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in \u00adHER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"NEJM"},{"issue":"10","key":"2023080322072255900_CIT0008","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2023080322072255900_CIT0009","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/tlcr.2020.04.07","article-title":"Lung cancer biomarker testing: Perspective from Europe","volume":"9","author":"Thunnissen","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2023080322072255900_CIT0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12885-018-4023-4","article-title":"NSCLC molecular testing in Central and Eastern European countries","volume":"18","author":"Ryska","year":"2018","journal-title":"BMC Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e699\/51034768\/oyad134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e699\/51034768\/oyad134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:07:54Z","timestamp":1691100474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/e699\/7195206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad134","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,6,13]]}}}